This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Expands Its Patient Financial Assistance Program

SALT LAKE CITY, July 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a program to provide financial assistance to underinsured patients. Beginning July 22, Myriad will offer financial assistance to reduce qualified underinsured patients' out-of-pocket cost to no more than $375. To be eligible, patients must have private insurance, meet their insurance's coverage criteria for testing, and meet low income requirements (household incomes up to 200 percent of the Federal poverty level). This expansion of Myriad's financial assistance program to underinsured patients complements the free testing Myriad currently offers for low income uninsured patients.

"We recognize that a large number of Americans are underinsured and have many expenses that raise their healthcare costs," said Peter D. Meldrum, president and CEO of Myriad. "We want to ensure that those with the greatest financial need have access to our diagnostic tests and this new component of our financial assistance program will make that possible. A lack of financial resources should not be an impediment to quality healthcare."

According to the Commonwealth Fund's 2012 Biennial Health Insurance Survey, an estimated 30 million Americans are underinsured. In 2012, 80 million skipped needed health care -- including doctor's visits and prescriptions -- in the past year due to cost. 

The expanded financial assistance program covers all of Myriad's diagnostic tests and builds upon the two existing programs that the company already has in place:
  • For uninsured patients who meet medical society guidelines and whose household incomes fall below 200 percent of the Federal poverty level, diagnostic testing is available at no charge. 
  • For all patients, interest-free tailored payment plans are available to accommodate specific financial situations. 

Myriad Genetics has helped more than 35,000 patients gain access to molecular diagnostic testing through its patient and financial assistance programs to date. For more information patients may go to .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: .

Myriad, the Myriad logo are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs